What are the diagnostic criteria for schizophrenia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 8, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Schizophrenia diagnosis requires the presence of at least two specific symptoms, including delusions, hallucinations, disorganized speech, grossly disorganized or catatonic behavior, and/or negative symptoms, for a significant period during a 1-month period, as outlined in the practice parameter for the assessment and treatment of children and adolescents with schizophrenia by the American Academy of Child and Adolescent Psychiatry 1. The diagnostic criteria for schizophrenia involve a combination of symptoms that must be present for a significant duration. The symptoms include:

  • Delusions
  • Hallucinations
  • Disorganized speech
  • Grossly disorganized or catatonic behavior
  • Negative symptoms, such as affective flattening, paucity of thought or speech According to the American Academy of Child and Adolescent Psychiatry 1, at least two of these symptoms must be present for a significant period during a 1-month period. However, if the delusions are bizarre, the hallucinations include a voice providing a running commentary on the person’s behavior or thinking, or two or more voices are conversing with each other, only one symptom is needed. The duration of symptoms may be less if the symptoms resolved with treatment, as noted in the practice parameter 1. It is essential to consider these criteria when diagnosing schizophrenia, as they help clinicians distinguish it from other psychiatric conditions with overlapping symptoms.

From the FDA Drug Label

The efficacy of aripiprazole in the treatment of schizophrenia was evaluated in five short-term (4-week and 6-week), placebo-controlled trials of acutely relapsed inpatients who predominantly met DSM-III/IV criteria for schizophrenia. Patients receiving aripiprazole tablets 15 mg/day experienced a significantly longer time to relapse over the subsequent 26 weeks compared to those receiving placebo, in a trial of patients who met DSM-IV criteria for schizophrenia. The efficacy of aripiprazole in the treatment of schizophrenia in pediatric patients (13 to 17 years of age) was evaluated in one 6-week, placebo-controlled trial of outpatients who met DSM-IV criteria for schizophrenia and had a PANSS score ≥70 at baseline

The diagnostic criteria for schizophrenia are based on the DSM-III/IV criteria. 2

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.